Perception of Physicians & Patients of AMD
Conditions
Keywords
SYMBICORT AMD
Brief summary
This study will evaluate the perception of the physicians and the patients about the approved adjustable dosing of Symbicort® 160/4,5. Symbicort maintenance dose will be adjusted up and down within the approved dose range of 1x2 - 4x2 inhalations per day, to the level of asthma symptoms. Patients and physicians perception of this new dosing schedule will be evaluated by means of questionnaires completion and direct questioning.
Interventions
DRUGSymbicort
Sponsors
AstraZeneca
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
12 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Minimum of 6 months history of asthma and treatment with an inhaled corticosteroids for at least 3 months prior to visit 1 and/or a history of short term variation in airway function and asthma symptoms responding promptly to convent * Patients where use of a combination (inhaled corticosteroid and long acting beta2-agonist is appropriate, i.e. not controlled on inhaled corticosteroids alone).
Exclusion criteria
* Asthma exacerbation requiring oral corticosteroid treatment in the four weeks prior to visit 1 * Upper Respiratory Tract Infection in the previous four weeks * Severe cardiovascular disease or other significant concomitant disease, which may interfere with the conduct of the study. * Women enrolled in the trial should not be planning pregnancy and should be taking adequate contraceptive measures where appropriate. * Previous enrollment in a clinical study * Known or suspected hypersensitivity to budesonide, formoterol or inhaled lactose
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Patient satisfaction with the adjustable maintenance dosing schedule | Throughout the study |
| Physicians' satisfaction with the adjustable maintenance dosing schedule | Throughout the study |
Outcome results
None listed